Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accumulated Expenses (2016 - 2025)

Vistagen Therapeutics' Accumulated Expenses history spans 12 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 69.21% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $9.3 million, up 69.21%, while the annual FY2025 figure was $8.8 million, 294.18% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.3 million at Vistagen Therapeutics, up from $8.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.3 million in Q4 2025 and bottomed at $35000.0 in Q2 2023.
  • The 4-year median for Accumulated Expenses is $2.6 million (2021), against an average of $3.8 million.
  • The largest annual shift saw Accumulated Expenses changed 0.0% in 2021 before it soared 6082.86% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $2.6 million in 2021, then tumbled by 95.08% to $129300.0 in 2023, then surged by 4129.7% to $5.5 million in 2024, then soared by 69.21% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Accumulated Expenses are $9.3 million (Q4 2025), $8.4 million (Q3 2025), and $6.6 million (Q2 2025).